FDA Grants Marketing Authorization to First DNA Test to Assess Genetic Predisposition to Select Cancers

The FDA has granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test designed to detect genetic variants associated with an elevated risk of developing certain types of cancer.

Related Keywords

,Jeff Shuren ,Invitae Common Hereditary Cancers Panel ,Radiological Health ,Precision Medicine In Oncology ,News ,